Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children’s Oncology Group
| Autor: | Lu Chen, Lanie Lindenfeld, Mary Bancroft, Biljana Gillmeister, David R. Freyer, Ha Dang, Edward A. Neuwelt, Bonnie Bliss, Kristin R. Knight, Bradley H Pollock, Jane Meza, Dale F. Kraemer, Eleanor Hendershot, Richard Aplenc, Lillian Sung |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Cancer Research Pediatrics medicine.medical_specialty Adolescent Oncology and Carcinogenesis Clinical Sciences Otoacoustic Emissions Spontaneous Audiologist Audiology Asha Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Ototoxicity Antineoplastic Combined Chemotherapy Protocols medicine Humans Oncology & Carcinogenesis Young adult Preschool Child Hearing Loss 030223 otorhinolaryngology Prospective cohort study Randomized Controlled Trials as Topic Errata business.industry Spontaneous Infant Common Terminology Criteria for Adverse Events medicine.disease Oncology Child Preschool 030220 oncology & carcinogenesis Female Observational study Cisplatin business Otoacoustic Emissions Cohort study |
| Zdroj: | Knight, KR; Chen, L; Freyer, D; Aplenc, R; Bancroft, M; Bliss, B; et al.(2017). Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(4), 440-445. doi: 10.1200/JCO.2016.69.2319. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/89f0f24x Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 35, iss 4 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.69.2319 |
| Popis: | Purpose Optimal assessment methods and criteria for reporting hearing outcomes in children who receive treatment with cisplatin are uncertain. The objectives of our study were to compare different ototoxicity classification systems, to evaluate the feasibility of including otoacoustic emissions and extended high frequency audiometry, and to evaluate a central review mechanism for audiologic results for cisplatin-treated children in the cooperative group setting. Patients and Methods Eligible participants were 1 to 30 years, with planned cisplatin-containing treatment. Hearing evaluations were conducted at baseline, before each cisplatin cycle, and at the end of therapy. Audiologic results were assessed and graded by the testing audiologist and by two central review audiologists using the American Speech-Language-Hearing Association Ototoxicity Criteria (ASHA), Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE), and Brock Ototoxicity Grades (Brock). One central reviewer also used the International Society of Pediatric Oncology Ototoxicity Scale (SIOP). Results At the end of treatment, the prevalence of any degree of ototoxicity ranged from 40% to 56%, and severe ototoxicity ranged from 7% to 22%. Compared with CTCAE, SIOP detected significantly more ototoxicity ( P = .004), whereas Brock criteria detected significantly fewer patients with any or severe ototoxicity ( P < .001 for both). SIOP detected ototoxicity earlier than did the other scales. Agreement between the central reviewers and the institutional audiologist was almost perfect for ASHA and Brock, whereas the poorest agreement occurred with CTCAE. Conclusion The SIOP scale may be superior to ASHA, Brock, and CTCAE scales for classifying ototoxicity in pediatric patients who were treated with cisplatin. Future studies should evaluate inter-rater reliability of the SIOP scale. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|